Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | ALDH2 | P05091 | 4/20 | 0.47 |
| ▸ | ALDH3A1 | P30838 | 4/20 | 0.47 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.46 |
| ▸ | APLNR | P35414 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5429853 | 0.82 | ALDH3A1 (0.54) | CHRM5ALDH1A1ALDH2ALDH3A1PARK7 | |
| SCHEMBL5432840 | 0.77 | MAPT (0.54) | ALDH1A1APLNRMAPTMEN1KMT2A | |
| SCHEMBL5424603 | 0.76 | TP53 (0.60) | CHRM5ALDH1A1ALDH2ALDH3A1PARK7 | |
| SCHEMBL5427833 | 0.74 | ALDH3A1 (0.59) | CHRM5ALDH1A1ALDH2ALDH3A1MAPT | |
| SCHEMBL13486597 | 0.74 | GSK3A (0.58) | ALDH1A1APLNRMAPTMEN1KMT2A | |
| SCHEMBL9387548 | 0.73 | RAB9A (0.60) | APLNRCASP3MEN1KMT2AKDM4E | |
| SCHEMBL5427094 | 0.73 | PARK7 (0.54) | CHRM5PARK7MAPTTP53 | |
| SCHEMBL19577090 | 0.73 | APLNR (0.54) | ALDH1A1APLNRMAPTMEN1KMT2A | |
| SCHEMBL22616743 | 0.72 | APLNR (0.53) | ALDH1A1APLNRMAPTMEN1KMT2A | |
| SCHEMBL16047437 | 0.71 | ALDH1A1 (0.49) | CHRM5ALDH1A1ALDH2ALDH3A1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203184-A1 | Novel Indolin-2-one Derivatives, Their Preparation and the Pharmaceutical Compositions Comprising Them | SANOFI-AVENTIS (FR) | 2007-08-30 | — | — | US | disclosed |
| EP-1272468-B1 | INDOLIN-2-ONE DERIVATIVES, PREPARATION AND THEIR USE AS OCYTOCIN RECEPTOR LIGANDS | SANOFI AVENTIS (FR) | 2004-11-17 | — | — | EP | disclosed |
| US-20040059132-A1 | Novel indolin-2-one derivatives, their preparation and the pharmaceutical compositions comprising them | SANOFI-AVENTIS (FR) | 2004-03-25 | — | — | US | disclosed |
| US-6673790-B1 | ANTAGONIST OF OXYTOCIN RECEPTORS USED IN COMBINATION WITH ANTAGONIST OF VASOPRESSIN V1A RECEPTORS FOR TREATMENT OF DYSMENORRHEA OR ENDOMETRIOSIS OR CONTROL OF PREMATURE LABOR AND FOR CONTROLLING PREPARATORY LABOR FOR CAESAREAN DELIVERY | SANOFI-SYNTHELABO (FR) | 2004-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040059132-A1 | Novel indolin-2-one derivatives, their preparation and the pharmaceutical compositions comprising them | OXTR, AVPR2, AVPR1B | CHRM5 385/4885ALDH1A1 4188/4885ALDH2 4362/4885 |
| US-20070203184-A1 | Novel Indolin-2-one Derivatives, Their Preparation and the Pharmaceutical Compositions Comprising Them | OXTR, AVPR2, AVPR1B | CHRM5 339/4885ALDH1A1 4275/4885ALDH2 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.